NETRAMARK HOLDINGS INC. Aktie

At the H.C. Wainwright conference, NetraMark introduced its NetraAI platform, which is intended to identify small patient subgroups that can determine the success or failure of clinical trials. The company cites FDA recognition at a Critical Path Innovation Meeting, published scientific articles and initial commercial successes, as well as a distribution partnership with Worldwide Clinical Trials. NetraMark reports a pipeline of around 50 active opportunities, a gross margin profile of about 95% and a cash runway of roughly 24 months after a capital raise in early 2026. The stock traded at $0.70 (+7.69%) and is moving near the lower end of its 52-week range. » Mere på de.investing.com

NetraMark appointed Kevin Felix as strategic adviser to strengthen relationships with institutional investors and investment banks in Canada and the U.S., as well as its capital markets and corporate strategy. Felix brings more than 25 years of experience in capital markets, asset management and securities law, most recently serving as president of the Investment Office at Global Atlantic. The appointment coincides with the company’s rollout of its commercialization strategy for its AI solution NetraAI in clinical trials. » Mere på de.investing.com

NetraMark received a contract through a partnership with a CRO to analyze Phase 2 study data in the field of neurodegeneration. The company will use its NetraAI platform to identify model-based subgroups and patterns in treatment response to support patient stratification and study design. It is NetraMark's first contract that did not come directly from a biopharmaceutical company; financial details were not disclosed. NetraMark has a market capitalization of USD 893 million and remained unprofitable over the past 12 months with a net loss of USD 3.9 million. » Mere på de.investing.com